Corbus Pharmaceuticals
CRBP
107 hedge funds and large institutions have $129M invested in Corbus Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 24 closing their positions.
2,891% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $640K
7% more capital invested
Capital invested by funds: $121M → $129M (+$7.95M)
1.55% more ownership
Funds ownership: 72.75% → 74.3% (+1.6%)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
1% less funds holding
Funds holding: 108 → 107 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10M |
| 2 |
JHC
Jones Hill Capital
New York
|
+$6.19M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.24M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.76M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.01M |
| 2 |
AC
Armistice Capital
New York
|
-$3.42M |
| 3 |
Renaissance Technologies
New York
|
-$2.24M |
| 4 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$1.31M |
| 5 |
Millennium Management
New York
|
-$912K |
CRBP Hedge Fund Activity: Q2 2026 in Review
107 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2026, worth a combined $129M — up 6.6% from $121M a quarter earlier.
Fund positioning in CRBP was balanced in Q2 2026: 24 funds opened new positions, 24 closed out, 28 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $10M. The largest seller was Citadel Advisors, cutting an estimated $6.01M.
- 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2026, down from 108 in Q1 2026.
- Funds reported $129M of Corbus Pharmaceuticals stock for Q2 2026, up 6.6% quarter-over-quarter.
- 24 funds opened new Corbus Pharmaceuticals positions in Q2 2026 and 24 closed out, a net change of 0 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $10M added.
- The largest Corbus Pharmaceuticals seller in Q2 2026 was Citadel Advisors, an estimated $6.01M sold.
Based on aggregated 13F filings for Q2 2026.